Caedo Oncology

Visit company website

Develops improved treatment options for cancer patients through unique immunotherapy opportunities.

  • CD47 is a well-validated target - over expressed across many cancer types – solid and hematological
  • CD47 over expression correlates with poor progression free survival and overall survival prognosis
  • Addresses on cology opportunities with significant unmet medical needs.
  • Breast, Lung, Prostate, Bladder, Cervical, Colo-rectal, Head & Neck, Melanoma, Glioblastoma, Lymphoma, Acute, LymphoblasticLeukemia, , Acute, MyeloidLeukemia